WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval Thursday of
Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy dkoding.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dkoding.in Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy